Voyager Therapeutics, Inc. financial data

Symbol
VYGR on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
75 Hayden Avenue, Lexington, MA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 574 % +41.7%
Debt-to-equity 42.5 % -46.2%
Return On Equity 3.31 % -95.2%
Return On Assets 2.33 % -94%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 54.5M shares +24.2%
Common Stock, Shares, Outstanding 54.5M shares +24.5%
Entity Public Float 489M USD +330%
Common Stock, Value, Issued 54K USD +22.7%
Weighted Average Number of Shares Outstanding, Basic 57.7M shares +32.6%
Weighted Average Number of Shares Outstanding, Diluted 57.7M shares +32.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 44.3M USD -77.3%
Research and Development Expense 113M USD +52%
General and Administrative Expense 37.3M USD +12.6%
Operating Income (Loss) -6.65M USD -108%
Nonoperating Income (Expense) 16.4M USD +76.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9.71M USD -90%
Income Tax Expense (Benefit) 683K USD -59.3%
Net Income (Loss) Attributable to Parent 9.02M USD -90.6%
Earnings Per Share, Basic 0.16 USD/shares -93.3%
Earnings Per Share, Diluted 0.16 USD/shares -93%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 76.1M USD -68.8%
Marketable Securities, Current 295M USD +936%
Cash, Cash Equivalents, and Short-term Investments 371M USD +36%
Other Assets, Current 2.63M USD -37.9%
Assets, Current 382M USD +35.2%
Property, Plant and Equipment, Net 16.3M USD -5.64%
Operating Lease, Right-of-Use Asset 35.5M USD +144%
Assets 436M USD +38.2%
Accounts Payable, Current 2.61M USD +57%
Employee-related Liabilities, Current 4.76M USD +27.7%
Accrued Liabilities, Current 10.3M USD +13.4%
Contract with Customer, Liability, Current 20.5M USD -35.2%
Liabilities, Current 40.1M USD -11.6%
Contract with Customer, Liability, Noncurrent 19.5M USD -62.1%
Operating Lease, Liability, Noncurrent 40.2M USD +115%
Other Liabilities, Noncurrent 41.2M USD +109%
Liabilities 101M USD -13.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax -522K USD -292%
Retained Earnings (Accumulated Deficit) -283M USD +3.09%
Stockholders' Equity Attributable to Parent 335M USD +68.5%
Liabilities and Equity 436M USD +38.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 58.8M USD -52.4%
Net Cash Provided by (Used in) Financing Activities 113M USD +260%
Net Cash Provided by (Used in) Investing Activities -96.1M USD -763%
Common Stock, Shares Authorized 120M shares 0%
Common Stock, Shares, Issued 54.5M shares +24.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 75.6M USD -55.4%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 79M USD -67.9%
Deferred Tax Assets, Valuation Allowance 82.6M USD -29.6%
Deferred Tax Assets, Gross 89M USD -28.7%
Depreciation 1.2M USD +11.3%
Payments to Acquire Property, Plant, and Equipment 2.14M USD +321%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 8.63M USD -91%
Property, Plant and Equipment, Gross 31.5M USD -10.1%
Operating Lease, Liability, Current 6.74M USD +124%
Deferred Tax Assets, Operating Loss Carryforwards 13.7M USD -71%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 619M USD +26%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 6.43M USD -13.4%
Share-based Payment Arrangement, Expense 13.5M USD +38.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%